The FDA has kicked off a priority review of Genfit and Ipsen’s elafibranor as a treatment for rare cholestatic liver disease primary biliary cholangitis (PBC), setting a date of 10th June to ...

As the drug development landscape becomes more complex, pharmaceutical and biotech companies understand their business strategies have to evolve. This need is putting a spotlight on how clinical ...

NICE has said that patients with acute respiratory infections can be cared for at home rather than in a hospital, with the help of digital platforms that transmit information on a patient's ...

Click Therapeutics' digital therapeutic (DTx) for migraine has hit the mark in a late-stage study using an endpoint commonly used to test drug therapies, which it claims is a first for the ...

Among those celebrating today’s agreement on a voluntary rebate scheme for branded medicines in the UK, there are dissenting voices, including a group representing manufacturers of off-patent ...

Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (IPO) filed by CAR-T ...

Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinical development.

2023 was a tough year for biotechs with declines in private fundraising and public listings, but the UK industry stood up well under the pressure, according to new figures from the BioIndustry ...

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusions needed to one per month.

Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patients with ...

Leela Barham takes a look at the transparency of the UK’s new pricing and access scheme, the 2024 VPAG, based on public sources. Whilst it’s early days, there is more in the public domain ...

AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-based drug for cancer.